anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Suxamethonium is considered by many to be the best drug for providing ideal intubating conditions, short surgical procedures, and rapid sequence induction. However, its usefulness is limited by the frequent occurrence of adverse effects like postoperative myalgia. Therefore this study aimed to assess the prevalence and associated factors of postoperative suxamethonium-induced myalgia. An institutional-based cross-sectional study was conducted on 210 patients who underwent surgery with general anesthesia. The data was collected by using structured and pretested questionnaires and analyzed using SPSS version 20.0. Logistic regression was conducted to identify significant predictors based on a P-value of less than 0.05 with a 95% confidence level. Among 210 patients the prevalence of suxamethonium-induced postoperative myalgia in the first 48 h was 88 (41.9%). Patients having previous anesthesia and surgical exposure (AOR 5.29, 95% CI 1.86-15.05), patients having a co-existing disease (AOR 2.69, 95% CI 1.08-6.67), patients that had not taken premedication (analgesia) (AOR 4.64, 95% CI 1.69-12.74), anesthesia maintenance using halothane (AOR 4.5 95% CI 1.7-11.4) and relaxation maintained with suxamethonium (AOR 3.1, 95% CI 1.2-8.1) were significantly associated with the prevalence of postoperative myalgia. The magnitude of suxamethonium-induced postoperative myalgia was high. So it is better to do with preventive techniques. As much as possible it is better to avoid using suxamethonium and necessary to use better to Premedicate with nonsteroidal anti-inflammatory drugs and non-depolarizing neuromuscular medications.
Patients in the Acupuncture combined with ginger group received acupuncture treatment (snap-needle therapy) combined with ginger compresses, which were removed within 6h and snap-needles were removed after 24 hours. Study results were collected at six assessment periods of 0-0.5h, 0-1h, 1-3h, 4-6h, 6-12h, and 12-24h after anesthesia. Conducted by an independent researcher.
All patients will receive inhibitory repetitive transcranial magnetic stimulation (rTMS) treatment at 1 Hz frequency. The contralesional primary motor cortex region will be stimulated with a Neurosoft-Neuro MS/D device. There will be a total of 10 treatment sessions over a 2-week period. Before each intervention, the resting motor threshold (rMT) value will be determined. rMT will be detected by obtaining a motor-evoked potential of \>50 μV amplitude on EMG recording of the contralateral first dorsal interosseous muscle in at least 5 out of 10 stimulations to the primary motor cortex. 90% of the motor threshold will be set in the stimulation. Each stimulation is planned for a total of 20 minutes and a total of 1200 pulses in the form of 1 Hz stimulation.
Cerebrovascular diseases are the third leading cause of death in Taiwan in 2007. It is also the most important reason for disability among elderly adults. Sex hormones are well reported to be associated with cardiovascular disease risk. Several studies showed that estrogens have been shown to have beneficial effects on the cardiovascular system via favorable effects on anti-inflammatory effects. Genetic polymorphisms of estrogen related genes are speculated to influence estrogen level and will count for human susceptible to risk of stroke in young adults. In addition, several studies showed that the decrease in estrogen-induced vascular inflammatory markers including adhesion molecules and chemokines might be the mechanism for vascular protection. Recently, a novel and unique mechanisms for 17β-Estradiol (E2) anti-inflammatory activity which is E2 prevents inflammatory gene transcription induced by inflammatory agents by inhibiting NF-κB intracellular transport was found. Therefore, we proposed a study to explore the association between the genetic polymorphisms of estrogen-related genes, including estrogen synthesis, metabolizing, receptor genes, and NF-κB and ischemic stroke in young adults.
The invention relates to a Chinese medicinal composition for curing rheumatism and a preparation method thereof. The Chinese medicinal composition mainly comprises the following components: 10 to 30 g of Qianjin root, 10 to 30 g of glandularstalk St. Paulswort herb, 1 to 10 g of American ginseng, 5 to 20 g of spatholobus stem, 5 to 30 g of horny goat weed, 2 to 10 g of the root of bidentate achyranthes, 1 to 20 g of India ginseng, 2 to 10 g of pseudo-ginseng and 10 to 90 g of safflower. The preparation of the Chinese medicinal composition can be directly applied to clinic and can also be applied to clinic after evolution (increment or reduction in dosage or formula). The preparation method comprises the following steps of: mixing the Chinese medicinal materials proportionally and grinding the Chinese medicinal materials into powder; heating and extracting the powder by using 100 percent pure alcohol in an amount which is about 5 times the weight of the Chinese medicinal materials; and distilling the extract slowly at a low temperature to obtain the concentrated preparation. The Chinese medicinal composition can effectively cure rheumatic pain, fever and relevant inflammation, even can eliminate rheumatism. In particular, the invention relates to various herbal ingredients which can contribute to improving the health and flexibility of joints, eliminating swelling, maintaining and enhancing the activity of joints and connective tissues.
NEW MATERIAL:A compound shown by formula I (A is >C=O or >CHOH; R<1> is H, aralkyl or lower alkyl). USE:A synthetic intermediate for camptothecin derivative useful as an anti-cancer drug. PREPARATION:p-Anisidine shown by formula II is reacted with propionitrile in the presence of boron chloride and aluminum chloride to give 2-amino-5- methoxypropiophenone. This compound is reacted with a pyrrolidine derivative to give a compound shown by formula III. The compound is heated in the presence of a base to give a compound shown by formula IV. This compound is heated in the presence of an acid, the reaction product is reduced and is heated in the presence of an acid to give a compound shown by formula V. This compound is reacted with a butyric acid derivative shown by formula VI (R<5> is aralkyl; R<6> is lower alkyl) to give a compound shown by formula I wherein group A is >C=O and R<1> is R<5>.
Avoidance of potential threat may become maladaptive when it is indiscriminate and resistant to change. Here, we investigated the resistance to change of high and low avoidance response effort when avoidance extinction involved unavoidable presentations of the aversive event (shock) in humans. Following fear conditioning, participants prevented upcoming shock delivery by responding on high (i.e., fixed ratio, FR-20) and low (FR-5) negative reinforcement schedules. Next, noneliminable shock was used for an avoidance extinction procedure whereby responding was followed by, rather than prevented, shock. During a subsequent standard extinction and response prevention test phase, we found that High effort (FR-20) avoidance would be more readily extinguished than Low effort (FR-5) avoidance. It was also predicted that fear, threat expectancy, and psychophysiological (skin conductance) responses would decrease on avoidable trials and increase on unavoidable trials before extinguishing to low levels. It was found that in the final extinction re-test phase when avoidance was possible, responding increased, particularly for low effort cues. Both fear and expectancy remained high. Individual differences on clinically relevant measures of trait anxiety, intolerance of uncertainty and experiential avoidance were associated with greater levels of fear and threat expectancy. Overall, unavoidable shock extinction may hold promise for further translational investigations of avoidance learning, extinction, and clinical treatment development.
FIELD: medicine, anesthesiology, surgery. SUBSTANCE: method involves carrying out an antibacterial, anti-inflammatory and sensitizing therapy and topical effect. Additional medicinal mixture of the following composition: lidocaine 1% solution, 27.5 ml; vitamin B 1  6% solution, 1.0 ml; pentamine 5% solution, 0.5 ml; prosorin 0.05%. 1.0 ml; epinephrine in dilution 1:200 000 taken in volume 30.0 ml is conducted every day to nerves innervating upper limb at the level of 7-th cervical vertebra. Method ensures to decrease the excess afferent and efferent impulses at the level of nervous conductors and at the level of sympathetic ganglions, exhibit positive effect on peripheral tissue circulation, discharge venous congestion and increase viability of boundary inflammation regions due to activation of tissue factors and localize necrotic focus more exactly. EFFECT: improved method of treatment. 1 tbl, 1 dwg
Interference with Serological Testing (Indirect Antiglobulin Test)

SARCLISA binds to CD38 on red blood cells (RBCs) and may result in a false positive indirect antiglobulin test (indirect Coombs test). This interference with the indirect Coombs test may persist for approximately 6 months after the last infusion of SARCLISA. The indirect antiglobulin test was positive during Isa-Pd treatment in 68% of the tested patients, and during Isa-Kd treatment in 63% of patients. In patients with a positive indirect antiglobulin test, blood transfusions were administered without evidence of hemolysis. ABO/RhD typing was not affected by SARCLISA treatment.

Before the first SARCLISA infusion, conduct blood type and screen tests on SARCLISA-treated patients. Consider phenotyping prior to starting SARCLISA treatment. If treatment with SARCLISA has already started, inform the blood bank that the patient is receiving SARCLISA and SARCLISA interference with blood compatibility testing can be resolved using dithiothreitol-treated RBCs. If an emergency transfusion is required, non–cross-matched ABO/RhD-compatible RBCs can be given as per local blood bank practices [see Drug Interactions (7.1)]. 

Interference with Serum Protein Electrophoresis and Immunofixation Tests

SARCLISA is an IgG kappa monoclonal antibody that can be incidentally detected on both serum protein electrophoresis and immunofixation assays used for the clinical monitoring of endogenous M-protein. This interference can impact the accuracy of the determination of complete response in some patients with IgG kappa myeloma protein [see Drug Interactions (7.1)].
A homogeneous rapid (45 min) one-pot electrochemical (EC) aptasensor was established to quantitatively detect circulating tumor cells (CTCs) in lung cancer patients using mucin 1 as a marker. The core of this study is that the three single-stranded DNA (Y1, Y2, and Y3) could be hybridized to form Y-shaped DNA (Y-DNA) and further self-assemble to form DNA nanosphere. The aptamer of mucin 1 could be complementary and paired with Y1, thus disrupting the conformation of the DNA nanosphere. When mucin 1 was present, the aptamer combined specifically with mucin 1, thus preserving the DNA nanosphere structure. Methylene blue (MB) acted as a signal reporter, which could be embedded between two base pairs in the DNA nanosphere to form a DNA nanosphere-MB complex, reducing free MB and resulting in a lower electrochemical signal. The results demonstrated that the linear ranges for mucin 1 and A549 cells were 1 ag/mL-1 fg/mL and 1-100 cells/mL, respectively, with minimum detectable concentrations were 1 ag/mL and 1 cell/mL, respectively. The quantitative analysis of CTCs in 44 clinical blood samples was performed, and the results were consistent with the computerized tomography (CT) images, pathological findings and folate receptor-polymerase chain reaction (FR-PCR) kits. The receiver operating characteristic (ROC) curve exhibited an area under the curve (AUC) value of 0.970. The assay revealed 100% specificity and 94.1% sensitivity. It is believed that this electrochemical aptasensor could provide a new approach to detect CTCs.
FIELD: medicine. SUBSTANCE: invention proposes a method of safety intravenous administration of fatty acid or fatty acids, in part, the main fatty acids of order n-6 and n-3. Indicated substances or their part are administrated as lithium salts. Plasma lithium concentrations are monitored periodically to prevent hemolysis and maintained preferably at level 0.7 mM, not above, for the long time and preferably at level 0.4-0.5 mM also, not above, for the first 24-48 h. Alternatively, their content is maintained at level representing a definite part of above indicated level values in the case if only part of lithium salts is administrated of fatty acids to be used. Method can be used for treatment of cancer and infectious viral diseases requiring plasma high fatty acid level maintenance. EFFECT: improved method of administration. 9 cl
Itch is a unique sensory experience that is responded to by scratching. How pruritogens, which are mechanical and chemical stimuli with the potential to cause itch, engage specific pathways in the peripheral and central nervous system has been a topic of intense investigation over the last few years. Studies employing recently developed molecular, physiological, and behavioral techniques have delineated the dedicated mechanisms that transmit itch information to the brain. This review outlines the genetically defined and evolutionary conserved circuits for itch ranging from the skin-innervating peripheral neurons to the cortical neurons that drive scratching. Moreover, scratch suppression of itch is attributed to the concurrent activation of pain and itch pathways. Hence, we discuss the similarities between circuits driving pain and itch.
The active control group consists of 24 teaching units (TUs) à 45 minutes over 12 weeks. Every week patients will meet for 2 TUs. The patients will also receive a script with theoretical basics and descriptions of the PMR techniques, hich should facilitate the correct practice at home.
BACKGROUND: The prognostic nutritional index (PNI) and serum chloride level are related to adverse outcomes in patients with heart failure. However, little is known about the relationship between the PNI and serum chloride level in predicting the poor prognosis of patients with acute decompensated heart failure (ADHF).
METHODS AND RESULTS: We reviewed 1221 consecutive patients with ADHF admitted to the First Affiliated Hospital of Kunming Medical University from January 2017 to October 2021. After excluding patients with in hospital death, missing follow-up data, missing chloride data, missing lymphocyte (LYM) count data, or missing serum albumin data, 805 patients were included. PNI was calculated using the formula: serum albumin (ALB) (g/L) + 5 × LYM count (10^9/L). Patients were divided into 4 groups according to the quartiles of the PNI, and the highest PNI quartile (PNI Q4: PNI ≥ 47.3) was set as the reference group. The patients in the lowest PNI quartile (PNI Q1: PNI < 40.8) had the lowest cumulative survival rate, and mortality risk decreased progressively through the quartiles (log-rank χ2 142.283, P < 0.0001). Patients with ADHF were divided into 8 groups by quartiles of PNI and median levels of serum chloride. After adjustment, the hazard ratio (HR) for all-cause mortality in ADHF patients in Group 1 was 8.7 times higher than that in the reference Group 8. Furthermore, the addition of serum chloride level and PNI quartile to the Cox model increased the area under the Receiver operating characteristic (ROC) curve by 0.05, and the area under the ROC curve of the new model was higher than that of the original model with traditional risk factors.
CONCLUSIONS: Both the lowest PNI quartiles and low chloride level indicate a higher risk of all-cause death in patients with ADHF.
A variety of foot and ankle injuries can be treated effectively through the use of a controlled ankle movement (CAM) walker boot. CAM walker boots protect the injured area by restricting foot and ankle motion, providing a stable platform to distribute forces while bearing weight, and allowing the user to rollover the foot during ambulation because of a rocker bottom-shaped sole. Such qualities lend the CAM walker boot to provide ankle support that can be advantageous compared with other commonly used methods. Despite their utility, CAM walker boots create a simulated leg-length discrepancy (LLD), which can result in altered biomechanics during ambulation. Additionally, a LLD can be associated with lower back and joint pain.

We have previously conducted a study that suggests a relationship exists between CAM walker boot treatment and pain at sites other than the extremity being treated. There have been several randomized controlled trials (RCTs) examining a relationship between the correction of inherent LLD with insole inserts and lower back pain. Furthermore, there has been a past RCT and there is a current RCT examining a relationship between the use of the EVENup orthotic shoe lift to correct CAM walker boot simulated LLD and pain at sites other than the extremity being treated. However, these studies were not conducted with patient populations with uniform injuries. To the best of our knowledge, an RCT has not been conducted with the EVENup orthotic shoe lift to examine this relationship in a uniform patient population with nonoperative ankle fractures. This RCT aims to assess the efficacy of the EVENup orthotic shoe lift, towards reducing and even preventing such pain that may be associated with this common course of treatment.
PURPOSE:To reduce irritating properties and to enhance surface active performance by using alpha-glycosyl quillaiasaponin such as alpha-glycosyl compd. of deacylquillaiasaponin as an effective component to prepare a surface active agent. CONSTITUTION:alpha-Glycosyl quillaiasaponin is produced by dissolving quillaiasaponin or a deacylated compd. thereof as a surface active agent together with alpha-glycosyl saccharose compd. into water and adding transition enzyme for alpha-glycosyl to perform transition reaction. As alpha-glycosyl saccharose compd., amylose, amylopectin and starch, etc., are used. A mixed reactant contg. alpha- glycosyl quillaiasaponin as it is may be used as the surface active agent but after performing the purifying treatment by means of filtration, a synthetic high polymer absorbent or activated carbon to remove nonreactive quillaiasaponin or the like, it is preferably used as the surface active agent.
Just as skeletal muscle fatigues after repeated use, decision-making capacity fatigues when repeated choices are made. This phenomenon, in which people experience diminished concentration and willpower after repeated decision-making, is termed decision fatigue. (1) People experiencing decision fatigue are more likely to bias subsequent choices toward the status quo. By choosing the status quo, the decision-maker reserves the option to make an alternate choice at a later time, thereby preserving possibilities. Patients and their surrogates often make complex medical decisions for which they may have little experience. Although clearly at high risk, decision fatigue has not been studied this population. To elucidate these questions, we propose a four arm study of patients in a population at high risk for making complex decisions. Participants will be randomly assigned to varied levels of decision making effort to assess for the development of resultant decision fatigue and whether it alters subsequent decisions.
PURPOSE: A composition for flap treatment containing curcumin is provided to promote flap regeneration and heal wound caused after flap surgery. CONSTITUTION: A composition for promoting flap regeneration contains curcumin as an active ingredient. The flap is an ischemic flap. A pharmaceutical composition for treating flap contains pharmaceutically effective amount of curcumin and carrier which is pharmaceutically acceptable. The composition has topical application formulation. The topical application formulation is creams, ointments, gels, lotions, liquids, sprays or patches.
Patients receive irinotecan IV over 90 minutes and bevacizumab IV over 10 minutes on days 1 and 15. Patients also receive trifluridine and tipiracil hydrochloride PO BID on days 2-6 and 16-20. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
All women aged 55 or younger having a coronary angiogram for acute coronary syndrome (ACS) will be approached prior to their procedure. A pregnancy test will be performed (standard for pre-menopausal women due to potential radiation exposure). If the cause of the heart attack is uncertain (eg no obvious infarct-related narrowing or occlusion), intravascular ultrasound or optimal coherence tomography will be performed within the context of the angiogram to better view the artery wall. A picture of the iliac and renal arteries will be accomplished by aortography (one dye shot down the aorta); in the case that the renal arteries are not well visualized, selective renal angiography will be performed (catheter at the entry to the renal artery). In the case of suspected non-atherosclerotic abnormalities, a head CT angiogram wil be performed. Referral to appropriate specialists for detected abnormality will occur. If symptoms continue, the subject will be followed by a cardiologist. A research coordinator will contact the subject at 1, 6 and 12 months and then annually to collect data on medications, hospitalization and symptoms.
The invention discloses a capsaicin beta-cyclodextrin inclusion compound, as well as liposome and gel thereof. The capsaicin beta-cyclodextrin inclusion compound is prepared by the following method: (1) beta-cyclodextrin is dissolved in an aqueous phase and prepared into a solution, and the solution is added with capsaicin or a capsaicin solution so as to obtain a mixed solution of capsaicin and beta-cyclodextrin; and (2) the solution-type capsaicin beta-cyclodextrin inclusion compound is obtained from the mixed solution prepared in a step (1) through at least one treatment mode of standing, heating, stirring, ultrasound or grinding. The apparent solubility of the capsaicin of the inclusion compound increases by 2 to 20 times. In vitro transdermal study shows that the capsaicin inclusion compound can obviously raise the transdermal rate of medicine by 5 to 20 times as compared with cream and hydrogel, and obviously reduce the irritation of capsaicin at skin. Besides transdermal drug administration, the prepared inclusion compound and the inclusion compound liposome can also be orally taken, injected or administrated in bladders. In addition, the invention is simple in production process, and the quality is stable and easy to control.
Patients receive sirolimus PO QD on days 1-28 and gold sodium thiomalate IM on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
1. Technical Result Simplification of technological process, increase in medicinal and preventive efficiency of the obtained product, improvement of organoleptic properties and extension of durability. 2. Essence Tea leaves are treated by gradual admixture of the solution containing iodine salt and sodium thiosulphate in the proportion 50-100:1 up to achievement of iodine concentration in the raw 20-35 mg %. After that the plant raw rich in biologically active substances in the proportion 20:1-4 is added. 3. Field of Application Medicine, endocrinology.
Participants will attend the Horizons Plus HIV Prevention Program. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. Participants will be asked to rate the workshop anonymously.